Clinical Trial Update: Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ofatumumab and bendamustine followed by maintenance ofatumumab for rituximab-relapsed indolent B-cell non-Hodgkin's lymphoma; trial comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2018-08-09